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Background: Artemisia annua has a very rich phytochemistry comprising several classes of compounds, mainly 
monoterpenes, sesquiterpenes, and flavonoids.  It has been used in China for about 2000 years in the treatment of 
fever.  
Objective: The aim was to determine if there is any synergistic effect on the Artemisia annua phytochemicals. 
Materials and methods: Artemisia annua used in this study was obtained from a hybrid of the plant grown in the 
Tanzania highlands (2000-2200 m altitude) in Arusha by Natural Uwemba System for Health (N.U.S.Ag). The dried 
leaves were ground, and sequentially extracted with hexane, dichloromethane (DCM), methanol and water and the 
extracts were then combined. The extract was then fractionated using high performance liquid chromatography 
(HPLC). The effect of the combined crude extract was tested at different doses on in-vitro cultures (a CQ sensitive 
isolate D6 and CQ resistant isolate W2) of Plasmodium falciparum. The fractions and different blends of these were 
tested at different doses to determine their role, if any, on the activity of the full blend of the plant.  
Results: Of nine fractions thus tested against D6 and W2, four had activities of less than 3.9µg /ml, three fractions had 
activities of between 4.77-14.76 µg/ml and the remaining two had activities above 250g/µml. The seven more active 
fractions were re-evaluated in a subtractive bioassay procedure, in which one of each fraction was excluded at a time 
from the full 7-component blend. The activity of the combined seven active compounds was 10.40+0.50 µg/ml against 
W2.  Of these, one showed IC50 of less than 3.9 µg/ml and all blends showed IC50 at below 27µg/ml.  
Conclusion: The results show that different components of A. annua contribute to the synergistic anti-Plasmodium 
activity. The results constitute a useful basis for identifying the components of the plant other than artemisinin that 
contribute to the activity of herb. 
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1. Introduction 
Malaria is one of the most debilitating tropical diseases 
causing fever and morbidity in the tropics and a 
significant source of mortality especially among infants 
and young children. In 2012, there were an estimated 
207 million cases world-wide, causing an estimated 627 
000 deaths, mainly among children under 5 years of age 
in Africa. Ninety percent of all deaths occur in Sub 
Sahara Africa (WHO 2013). More than a third of the 
world’s population (about 2 billion people) live in 
malaria endemic areas and 1 billion people are 
estimated to carry parasites at any one time. In Africa 
alone, there are an estimated 200-450 million cases of 
fever in children infected with malaria each year 
(Breman et al., 2001). 
 The resistance of P.  falciparum to more available, safe, 
and easily administered drugs, especially chloroquine 
and pyrimethamine-sulfadoxine (SP), has become a 
serious obstacle to the control of malaria. Artemisinin 
combination therapy (ACT), using carefully matched 
drugs, is now the recommended strategy both for 
clinical care and for the avoidance of drug resistance. 
However studies at the Thai–Cambodian border, a 
historical epicenter of multidrug resistance, have 
detected reduced susceptibility to artemisinins as 
manifested by prolonged parasite-clearance times, 
raising considerable concerns on resistance 
development (O’Neill, 2010). 
Artemisinin was first isolated from Artemisia annua L., 
(sweet annie, sweet wormwood,) in China in 1972. The 
highest artemisinin compound is found in plant A. 
annua plants aged 12 to 13 weeks (Bouwmeester 2006). 
The total amount of artemisinin found in different 
varieties of A. annua varies between 0.01 to 1.4% by 
weight based on weight of dry leaves. This plant is used 
as a traditional medicine that has been consumed as 
anti-malarial drug  and after analyzing the compound, 
artemisinin and its derivatives have been found to 
inhibit the growth of P. falciparum both in vitro and in 
vivo (Casteel 1997). Artemisinin, is a sesquiterpene 
trioxane lactone containing a peroxide bridge, and was 
shown to be effective in killing malaria parasites 
(Mueller et al, 2000). Besides artemisinin itself, some 
derivatives such as artemether, dihydroartemisinin, 
arteether, and artesunate have anti-plasmodial activity 
(Wang et al 2005). The endoperoxide bridge in 
artemisinin reacts with ferrous iron atom to form free 
radicals (Zhang et al, 1992, Posner et al, 2000).  
Artemisinin becomes toxic to malaria parasites as they 
contain a high amount of iron in the form of heme 
molecules, and generation of free radicals leads to 
macromolecular damages and cell death (Anderson et 
al, 1999). 
A. annua has a very rich phytochemistry comprising 
several classes of compounds, mainly monoterpenes, 
sesquiterpenes (including artemisinin), and flavonoids 
(Bhakuni et al., 2002).  The composition of each 
category of these ‘secondary’ metabolites is variable, 
both qualitatively and quantitatively.  The principal 
monoterpenoid constituents of A. annua from different 
regions are artemisia ketone (30-80%), artemisia 
alcohol (7-56%), camphor (3- -
guainene (<5%), germacrane D (0-18%) and 1,8-cineole 
(~3-13%) (Woerdenbag et al., 1993; Hethelyi et al., 
1995; Ahmad and Mishra, 1994).  Of the sesquiterpenes, 
in addition to artemisinin, a series (up to 30) of 
compounds related to artemisinin occur in variable 
amounts in different chemotypes.  However, only some 
of these (including arteannunin B and artemisinic acid) 
occur in consistently higher relative amounts (Bhakuni 
et al., 2002).  Likewise, a large number of closely related 
non-glycosidic flavonoids and some glycosidic ones 
have been isolated from different A. annua varieties.   
Indirect evidence from studies by Yao-De (Yao-De et al. 
1992) suggests strongly that other constituents 
contribute to anti-plasmodium activity of the crude 
extracts of products derived from A. annua.  Chloroform 
extracts of cell suspension cultures developed from A. 
annua, with no significant amounts of artemisinin, has 
been found to have moderate antimalarial activity in 
vitro (IC50 ~ 10-5 M, compared to 10-8-10-7M for 
artemisinin) attributable to methoxy flavonoids (Liu et 
al., 1992).  At lower concentrations, these flavonoids 
had a marked and selective potentiating effect on the 
antiplasmodial activity of artemisinin (Elford et al., 
1987; Yang et al, 1989; Liu et al., 1992). Of the 
sesquiterpenes, so far, one (arteannuin B) has been 
tested and shown to synergise the activity of 
artemisinin (Chang and But, 1986).   
A major concern on the use of A. annua for malaria is 
that ingestion of sub-lethal doses of artemisinin may 
accelerate the development of resistance to this drug.  
Indeed, some degree of resistance to artemisinin may 
have already occurred in China.  The IC50 of pure 
artemisinin varies according to the strain of P. 
falciparum and can be as low as 6nM (Wongsrichanalai 
et al., 1997).  Interestingly, Chinese strains (IC50 = 
630nM) are much less sensitive than African ones (IC50 
= 25nM).  
Plant derived medicines continue to play an essential 
role in health care. It is estimated that approximately 80 
% of the world inhabitants in developing countries rely 
heavily on traditional medicines for primary health care 
(Arvigo and Balick 1993, Farnsworth et al 1985). 
Traditional medicine has been used to treat malaria for 
many years and Artemisia annua has been an important 
herb in Chinese treatment of malaria ((WHO, 2003). In 
Kenya plant extracts are still widely used in the 
treatment of malaria and other ailments (Kokwaro 
1993). 
Artemisinin and its derivatives are safe and well 
tolerated antimalarial drugs. They should be 
administered with combination with another effective 
blood schizontide to reduce recrudescence and to slow 
the development of resistance.  At present drug of 
choice for the combined therapy is mefloquine in the 
dose of 12-25 mg base/kg (WHO/MAL, 1998), however 
the combined regimens of mefloquine plus an 
artemisinin derivative have been associated with more 
side effects than those with an artemisinin derivative 
alone (Price et al, 1999). 
Artemisinin derivatives, artesunate, artemether and 
arteether, are all metabolised into dihydroartemisinin 
(DHA) (Balint, 2001) which is just as potent as its 
parent compounds, but has a longer half-life of 
approximately 4– 11 h. Artemisinin on the other hand is 
not metabolised into DHA but rather into inactive 
metabolites deoxyartemisinin and 
dihydroxydeoxyartemisinin (Balint, 2001). Artemisinin-
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based combination treatments (ACTs) are now 
generally accepted as the best treatments for 
uncomplicated falciparum malaria. They are rapidly and 
reliably effective. Efficacy is determined by the drug 
partnering the artemisinin derivative and, for 
artesunate–mefloquine, artemether–lumefantrine, and 
dihydroartemisinin– piperaquine, this usually exceeds 
95%. Artesunate–sulfadoxine–pyrimethamine and 
artesunate–amodiaquine (Nosten and White 2007). 
Parasite resistance to existing anti-malarial drugs has 
already reached alarmingly high levels in Southeast Asia 
and on the African continent, and therefore there is a 
dire need for new drugs in the prophylaxis and 
treatment of malaria (WHO, 1998). 
In our efforts to determine if other phytochemicals in 
Artemisia annua are also effective in malaria treatment 
the fractions were blend and tested against in-vitro 
cultures of Plasmodium falciparum D6 (CQ sensitive 
strain)  and W2 (CQ resistant strain). 
2. Materials and Methods 
2.1  Collection of plant material 
Uppermost foliar portions of Artemisia annua were 
collected in November 2006, from Arusha Tanzania on 
onset of flowering. A voucher specimen of the plant (No 
NMK/BOT/CTX/1/2) was deposited at the National 
Museums of Kenya Nairobi.  
The collected plant parts were air dried under shade for 
two weeks and ground using a laboratory mill. 
2.2  Preparation of Extracts  
Air dried and ground plant materials were extracted 
using hexane, dichloromethane methanol and water. 
The solvents were filtered and then the organic extracts 
were removed using rotary evaporation. The dry extract 
was then fractionated using high performance liquid 
chromatography (HPCL). The crude and the fractioned 
extract were tested on in-vitro cultures of Plasmodium 
falciparum. 
For bioassays test samples were first dissolved in 
dimethyl-sulphoxide (DMSO) solvent concentration of 
less than 0.02% and then in water and filtered in a 0.44 
mesh size filter and then stored at 40C.  
2.3 Parasite cultivation 
Laboratory adapted Plasmodium falciparum cultures of 
D6 originally from Sierra Leone and W2 strain originally 
from Indochina were used in the study. The strains 
were cultured and maintained in the malaria laboratory 
at Kenya Medical Research Institute (KEMRI) Nairobi.   
The culture medium was a variation of that described 
by  Trager and Jensen (Trager and Jensen 1976) and 
consisted of  RPMI 1640 supplemented with 10% 
human serum 25 mM N-2-hydroxyethy/piparazine-N-2-
ethanosulfonicic acid (HEPES)and 25 mM NaHCO3. 
Human type O+ erythrocytes (<28 days old) served as 
host cells and the cultures were incubated at 370C in an 
atmosphere of 3%CO2, 5% O2 and 92% N2 (Trager and 
Jensen 1976). 
2.4. Drugs Assay 
The in-vitro semi-automated micro-dilution assay 
technique that measured the ability of the extract to 
inhibit the incorporation of (G_3H) hypoxanthine into 
malaria parasite was used (Des Jardins et al 1979, 
Muregi et al 2003). Aliquots (25µl) of culture medium 
were added to all 96 wells of the flat bottomed micro-
culture plate (Costar Glass Works, Cambridge, UK). 
Aliquots (25µl) of the tests solutions were added in 
triplicate  to the first wells and by using a tite-tek 
motorized hand dilutic (flow laboratories, Uxbridge, 
UK) serial 2_fold dilutions of each sample was added 
over a 64_fold concentration range . 
Aliquots (200 µl) of 1.5 % (vol/vol) suspension of 
parasitized erythrocytes in culture medium (0.4 % 
parasitemia) and a growth rate of >3 fold per 48 hours 
were added to all test wells. 
Parasitized and non-parasitized erythrocytes were 
incorporated into all tests. The plates were incubated at 
370C in a gas mixture of 3% CO2, 5 %O2 and 92% N2. 
After 48hrs each well was pulsed with 25µl of culture 
medium containing 0.5µci of (G_3H) hypoxanthine and 
the plates incubated for a further 18hrs. 
The contents of each well were then harvested with a 
beta cell harvester (Wallac Zurich) onto glass fibre 
filters and washed thoroughly with distilled water, 
dried and the filters were inserted into plastic bags with 
liquid scintillant and the radioactivity measured in 
counts per minute (cpm) per well at each concentration. 
2.5 Data analysis 
Computation of the concentration of drug causing 50% 
inhibition of (G-3H) hypoxanthine uptake (IC50)was 
carried out by interpolation after logarithimic 
transformation of both concentration and cpm values 
using the formula, 
 IC50=antilog (log X1+ [(log Y50-log Y1) (log X2-log X1)] / 
(log Y22 –log Y1), 
Where Y50=cpm value midway between parasitized and 
non-parasitized control  cultures and X1,Y1,X2,and Y2 are 
the concentration and cpm values for the data points 
above and below the cpm midpoints (Sixsmith et al 
1984). 
3.  Results and Discussion 
Nine fractions were obtained and used in the bio-
assays; these were labeled as F1, F2, F3, F4, F5, F6, F7, 
F8, and F9. The full blend (F10) indicated the mixed 
crude extract. The asterick (*) indicted the fractions that 
had an activity of less than 3.9 µg /ml. 
In the preliminary studies the crude extract and 
fractions were screened against P. falciparum D6 (a 
Chloroquine sensitive isolate). Nine fractions (F1-F9) 
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were used in the bioassay and the results were 
summarized in Table 1.  Only two fractions showed an 
IC50 of above 250 µg /ml (L3 and L4) and this showed 
that these fractions were not active in-vitro against P 
falciparum D6. The crude extract (full blend) gave a 1C50 
of 10.40±0.50µg /ml against D6, however the crude 
extract was not very soluble as the material was very 
gummy, this probably led to a high IC50. 
Table 1: in vitro activity for the nine fractions against P. 
falciparum D6 and W2 strains 
FRACTIONS 
IC50 for D6 
(µg /ml) 
IC50 for W2 
(µg /ml) 
F1 4.77±1.49 6.59±0.36 
F2 14.763 ND 
F3 >250 ND 
F4 >250 ND 
F5* <3.9 ND 
F6 6.95±4.34 ND 
F7* <3.9 ND 
F8* <3.9 2.21±0.01 
F9* <3.9 13.13±0.20 
F10 10.40±0.50 ND 
Dihydroartemisinin 2.025 ng/mL ND 
ND: not determined 
Table 2: in vitro activity for the various blends of the 
fractions against P. falciparum D6 and W2 strains 
BLEND  
IC50 for D6 
(µg /ml) 
IC50 for W2 
(µg /ml) 
Full blend –F1 16.19±1.74  
Full blend -F2 9.19±0.31  
Full blend- F5 10.52±0.35  
Full blend –F6 10.12±0.70  
Full blend –F7 26.75±8.43  
Full blend –F8 10.40±0.50  
Full blend- F9 9.72±0.17  
F18=F1+F2   7.95±0.08 
F19=F2+F6  15.96±0.31 
F20=F1+F6  <3.9 
F7+F8+F9 6.273 7.07±0.09 
F5+F8+F9 6.332  
F5+F7+F9  11.87±1.95 
F5+F7+F8 5.063 7.74±0.09 
F5+F7+F8+F9 5.039  
Dihydroartemisinin 2.025 ng/mL  
Key: Full blend - F1 = F2+F3+F4+F5+F6+F7+F8+F9 
  Full blend - F2 = F1+F3+F4+F5+F6+F7+F8+F9 
  Full blend - F5 = F1+F2+F3+F4+F6+F7+F8+F9 
  Full blend - F6 = F1+F2+F3+F4+F5 +F7+F8+F9 
  Full blend - F7 = F1+F2+F3+F4+F5+F6+F8+F9 
  Full blend - F8 = F1+F2+F3+F4+F5+F6+F7+F9 
  Full blend - F9 = F1+F2+F3+F4+F5+F6+F7+F8   
Four fractions (F5, F7, F8, and F9) showed an IC50 of 
below 3.9 µg/ml meaning that these fractions had 
notable activity against P. falciparum D6. These were 
assayed further with isolate P. falciparum W2 (CQ 
resistant isolate).  Fraction F1’s activity was also tested 
against the CQ resistant isolate W2. Three of these 
fractions had an IC50 below 14µg /ml, which reflected 
notable activity against this strain (Table 1). The 
results also indicated that higher concentrations of the 
fractions were generally required for a CQ resistant 
isolate. 
When the fractions were further blended, all the blends 
gave an IC50 of less than 27 µg/ml. This indicated 
possible additive effects. Two blends showed an activity 
of less than 10 µg /ml against the D6 strain (Full blend - 
F2, Full blend - F9) and had an activity of 9.19µg /ml 
and 9.72µg /ml respectively. Three blends had an 
activity of between 10 and 11.  Full blend – F5 (10.52µg 
/ml), Full blend – F6 (10.12µg /ml, and Full blend – F8 
had an activity of 10.40µg /ml with D6. The lowest 
activity (IC50= 26.75 µg /ml) of the blends occurred 
when one of the more active fractions (F5) was absent; 
this indicated the contribution of the omitted fraction 
which probably contained an active compound. 
After blending some of the most active fractions very 
high activity was observed against the W2 strain i.e. F18 
had an IC50 of 7.95µg /ml and F19 had an IC50 of 
15.96µg /ml. One blend (F20) had an activity of <3.9µg 
/ml and this indicated notable activity that calls for 
further research (Table 2). 
4. Conclusion 
Biochemical investigations on some of the fractions and 
blends of Artemisia annua compounds may provide 
useful templates for the development of novel 
antimalarial drugs that are effective against CQ resistant 
P. falciparum. 
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